Analysts expect Vitamin Shoppe, Inc (NYSE:VSI) to post $262.27 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Vitamin Shoppe’s earnings. The highest sales estimate is $262.89 million and the lowest is $261.64 million. Vitamin Shoppe reported sales of $304.87 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 14%. The firm is expected to issue its next earnings results on Wednesday, March 7th.

On average, analysts expect that Vitamin Shoppe will report full year sales of $262.27 million for the current financial year, with estimates ranging from $1.17 billion to $1.19 billion. For the next financial year, analysts forecast that the company will report sales of $1.16 billion per share, with estimates ranging from $1.14 billion to $1.17 billion. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Vitamin Shoppe.

Vitamin Shoppe (NYSE:VSI) last posted its earnings results on Wednesday, November 8th. The specialty retailer reported ($0.03) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.17 by ($0.20). The business had revenue of $288.20 million for the quarter, compared to analyst estimates of $297.61 million. Vitamin Shoppe had a negative net margin of 20.27% and a positive return on equity of 6.17%. The business’s revenue was down 8.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.50 EPS.

Several research firms recently weighed in on VSI. Zacks Investment Research lowered shares of Vitamin Shoppe from a “hold” rating to a “sell” rating in a report on Tuesday, August 15th. Morgan Stanley set a $8.00 target price on shares of Vitamin Shoppe and gave the company a “hold” rating in a report on Thursday, August 10th. Goldman Sachs Group restated a “sell” rating and set a $6.00 target price (down previously from $13.00) on shares of Vitamin Shoppe in a report on Thursday, August 10th. Deutsche Bank restated a “hold” rating and set a $7.00 target price (down previously from $14.00) on shares of Vitamin Shoppe in a report on Thursday, August 10th. Finally, Barclays reduced their target price on shares of Vitamin Shoppe from $13.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, August 10th. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $5.00.

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Vitamin Shoppe by 14.8% in the 1st quarter. Vanguard Group Inc. now owns 2,186,549 shares of the specialty retailer’s stock worth $44,059,000 after buying an additional 282,598 shares in the last quarter. FMR LLC lifted its holdings in Vitamin Shoppe by 32.4% in the 2nd quarter. FMR LLC now owns 1,254,690 shares of the specialty retailer’s stock worth $14,617,000 after buying an additional 307,050 shares in the last quarter. State Street Corp lifted its holdings in Vitamin Shoppe by 9.2% in the 1st quarter. State Street Corp now owns 721,483 shares of the specialty retailer’s stock worth $14,535,000 after buying an additional 60,575 shares in the last quarter. Canada Pension Plan Investment Board lifted its holdings in Vitamin Shoppe by 175.5% in the 3rd quarter. Canada Pension Plan Investment Board now owns 652,600 shares of the specialty retailer’s stock worth $3,491,000 after buying an additional 415,700 shares in the last quarter. Finally, GMT Capital Corp acquired a new position in Vitamin Shoppe in the 3rd quarter worth $3,423,000. Hedge funds and other institutional investors own 89.78% of the company’s stock.

Vitamin Shoppe (VSI) opened at $3.60 on Thursday. The company has a current ratio of 2.07, a quick ratio of 0.32 and a debt-to-equity ratio of 0.59. The firm has a market cap of $92.31, a price-to-earnings ratio of 4.14 and a beta of 0.69. Vitamin Shoppe has a 1-year low of $2.95 and a 1-year high of $26.25.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/07/262-27-million-in-sales-expected-for-vitamin-shoppe-inc-vsi-this-quarter-2.html.

About Vitamin Shoppe

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Get a free copy of the Zacks research report on Vitamin Shoppe (VSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with MarketBeat.com's FREE daily email newsletter.